Navigation Links
Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
Date:1/7/2008

HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that it has successfully completed a Phase I safety and tolerability study with EVT 302. The preliminary results confirm the good tolerability profile of EVT 302 and are an encouraging basis for further clinical development.

EVT 302, a reversible and highly selective inhibitor of MAO-B in development for smoking cessation, was investigated in an ascending dose study with repeated daily dosing in a total of 84 healthy young and elderly subjects. Healthy young male subjects were treated with EVT 302 2.5, 5, 15 mg, or placebo for two weeks, and healthy elderly male and female subjects were treated with EVT 302 2.5 mg, 10 mg, or placebo for four weeks. Each treatment was received by 12 young and/or elderly subjects as appropriate. The highest dose levels exceed the expected maximum therapeutic dose planned to be used in further clinical trials. For the treatment period and part of the subsequent washout phase the subjects were confined to the clinical research unit.

The study was aimed at investigating safety/tolerability, pharmacokinetics, and pharmacodynamics (inhibition of MAO-B in platelets) during prolonged dosing with EVT 302 as compared to placebo. The study was conducted and successfully completed as planned per protocol. The results are still blinded and will become available as final evaluated data over the next two months.

The preliminary data indicate that EVT 302 was well tolerated in young and elderly subjects up to the highest dose levels tested in this study. Adverse events (AEs) classified as possibly treatment related were transient and mostly of mild intensity; only very few moderate AEs were reported. No severe or serious AEs occurred.

No clinically relevant changes in lab values of haematology or clinical chemistry were noted. In particular, there were no changes in liver function test
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 29, 2014 ACEA Biosciences, Inc. ... the 2014 iCELLigence Research Grant for his proposal ... instrument is an impedance based real-time label-free cellular ... Department of Biomedical Engineering at Yale University currently ... projects in Professor Rong Fan's laboratory ...
(Date:9/29/2014)... , Sept. 29, 2014 Burnham Securities ... Channel Group ("TCG"), a leader in healthcare venture ... formed an alliance to expand the range of ... With the alliance, Burnham Securities will be supported ... clinical medicine and management in healthcare industry to ...
(Date:9/29/2014)... METTLER TOLEDO’s new line of XPE balances includes ... balances as well as automated dosing with the ... out their daily weighing tasks worry free, safe in ... reliable and compliant results, thanks to new technologies such ... biggest challenges in analytical and micro-analytical weighing – electrostatic ...
(Date:9/29/2014)... , Sept. 29, 2014  The 12th Cold ... officially kicks off September 29 at the John B. ... Boston for a weeklong conference ... Chain Global Forum is designed to cover the industry,s ... modern cold chain, all temperature range products, GDP compliance ...
Breaking Biology Technology:ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3New Line of XPE Balances from METLER TOLEDO is Designed for High Performance and Ease of Compliance 212th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2
... and SAN DIEGO, Feb. 1, 2012 /PRNewswire-iReach/ ... be exhibiting at the CRT 2012 Conference in Washington ... its new cardiovascular diagnostic test PREvent. PREvent is the ... market that predicts near term (2-3 years) risk of ...
... may one day be able to hear the imagined speech ... paralysis, according to University of California, Berkeley, researchers. ... brain,s temporal lobe the seat of the auditory system ... this correlation between sound and brain activity, they then were ...
... painstaking study by Rice University has brought a wealth of ... fluorescence. The current issue of the American Chemical ... work by the Rice lab of chemist Bruce Weisman to ... their fluorescence in this case, the light they emit ...
Cached Biology Technology:FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference 2Scientists decode brain waves to eavesdrop on what we hear 2Scientists decode brain waves to eavesdrop on what we hear 3Perfect nanotubes shine brightest 2
(Date:9/29/2014)... Oktoberfest is here, and that means beer. ... a cold one, taking that first sip ... have reacted to form compounds that cause ... explains why beers get skunky, and what ... from going bad. Learn all about it ...
(Date:9/29/2014)... news release is available in French . ... 2014 - The number of days an expectant mother ... predicts the epigenetic profile of her child, a new ... Institute and McGill University have detected a distinctive ,signature, ... of the massive Quebec ice storm. Five months after ...
(Date:9/29/2014)... by researchers at the University of Cambridge has shown ... covering most of Greenland is more sensitive to climate ... the rising sea levels that threaten coastal communities worldwide. ... increasing levels of meltwater created and spilled into the ... the new model also takes into account the role ...
Breaking Biology News(10 mins):Greenland Ice Sheet more vulnerable to climate change than previously thought 2Greenland Ice Sheet more vulnerable to climate change than previously thought 3
... living in densely populated urban areas have a profound impact ... health and fitness of native wildlife. For the first time, ... urbanization and the prevalence and severity of two distinct parasites ... today,s issue of the journal PLOS ONE . ...
... made the world,s temperature records available via Google Earth. ... temperature dataset is one of the most widely used records ... allows users to scroll around the world, zoom in on ... data more easily than ever before. Users can drill ...
... Biological Studies will join Stanford University in leading a ... through a $40 million award by California,s stem cell ... center will bring together experts and investigators from seven ... of genomics the study of the complete genetic ...
Cached Biology News:Presence of humans and urban landscapes increase illness in songbirds, researchers find 2Presence of humans and urban landscapes increase illness in songbirds, researchers find 3World temperature records available via Google Earth 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 3
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... is specifically designed to target and display ... cerevisiae. Displayed proteins can be analyzed for ... putative ligands. pYD1 uses the a-agglutinin yeast ... Aga1 and Aga2, to display recombinant protein ...
Biology Products: